Vorinostat Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Vorinostat comprises 268 peer-reviewed publications across 15 journals, 11 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Acquired Immunodeficiency Syndrome, Infections, Leukemia, Myeloid, Acute, and Multiple Myeloma. Most recent publication: Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study., Lancet Haematol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
    Ree AH, Dueland S, Folkvord S, et al. · Lancet Oncol · 2010
    PubMed: PMID 20378407 · NCT00455351 (PRAVO) · Pelvic Neoplasms
  2. Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal.
    McMahon JH, Evans VA, Lau JSY, et al. · AIDS · 2022
    PubMed: PMID 34586085 · NCT03198559 · HIV Infections
  3. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
    Krug LM, Kindler HL, Calvert H, et al. · Lancet Oncol · 2015
    PubMed: PMID 25800891 · NCT00128102 · Lung Neoplasms
  4. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.
    Hütter G, Nowak D, Mossner M, et al. · N Engl J Med · 2009
    PubMed: PMID 19213682 · NCT02336074 (RIVER) · Infections
  5. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
    Fidler S, Stöhr W, Pace M, et al. · Lancet · 2020
    PubMed: PMID 32085823 · NCT02336074 (RIVER) · Infections
  6. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
    Dimopoulos M, Siegel DS, Lonial S, et al. · Lancet Oncol · 2013
    PubMed: PMID 24055414 · NCT00773747 · Multiple Myeloma
  7. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.
    Choi SW, Braun T, Chang L, et al. · Lancet Oncol · 2014
    PubMed: PMID 24295572 · NCT00810602 · Graft vs Host Disease
  8. Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial.
    Brown S, Pawlyn C, Tillotson AL, et al. · Clin Lymphoma Myeloma Leuk · 2022
    PubMed: PMID 33478922 · NCT01720875 (MUKfour) · Multiple Myeloma

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT00128102Lung NeoplasmsNumber of Participants Who Discontinued Study Treatment Due to an AE
Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
Placebo49 Participants
Vorinostat60 Participants
NCT00128102Lung NeoplasmsNumber of Participants Who Experienced Adverse Events (AEs) Characterized as Grade 3 or Grade 4 According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
Placebo146 Participants
Vorinostat165 Participants
NCT00128102Lung NeoplasmsNumber of Participants Who Experienced an AE
Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
Placebo311 Participants
Vorinostat327 Participants
NCT00128102Lung NeoplasmsOverall Survival (OS)
Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
Placebo27.1 Weeks
Vorinostat30.7 Weeks
NCT00473889—Overall Survival
Start of treatment to death
Placebo + Paclitaxel + Carboplatin14.0 Months
Vorinostat + Paclitaxel + Carboplatin11.0 Months
NCT00773747Multiple MyelomaProgression-Free Survival (PFS)
From randomization to event of disease progression or death assessed up to 32 months (final study analysis)
Placebo + Bortezomib6.83 Months (±5.67 95% Confidence Interval)
Vorinostat + Bortezomib7.63 Months (±6.87 95% Confidence Interval)
NCT01236560AstrocytomaEvent-free Survival
1 year after enrollment
Arm I (Vorinostat, Phase II Arm A)41.3 percent probability
Arm II (Temozolomide, Phase II Arm B)59.3 percent probability
Arm III (Bevacizumab, Phase II Arm C)43.8 percent probability
Feasibility (Vorinostat)33.3 percent probability
NCT01236560AstrocytomaMaximum Tolerated Dose (MTD) of Vorinostat
10 weeks
Feasibility (Vorinostat)230 mg/sq m
NCT01728805Lymphoma, T-Cell, CutaneousProgression Free Survival
From date of randomization at every visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
KW-076114.1 percentage of subjects
KW-07614.7 percentage of subjects
KW-076138.3 percentage of subjects
KW-076155.3 percentage of subjects
KW-076128.0 percentage of subjects
Vorinostat7.2 percentage of subjects
Vorinostat7.2 percentage of subjects
Vorinostat7.2 percentage of subjects
Vorinostat15.3 percentage of subjects
Vorinostat28.8 percentage of subjects
NCT01802333Leukemia, Myeloid, AcuteEvent-free Survival (EFS)
EFS assessed for up to 5 years, 2 year EFS reported
Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride)0.36 Proportion of participants
Arm II (High-dose Cytarabine, Idarubicin)0.41 Proportion of participants
Arm III (Vorinostat, High-dose Cytarabine, Idarubicin)0.37 Proportion of participants
NCT01802333Leukemia, Myeloid, AcuteRate of Allogeneic HCT
Up to 5 years
High Risk Patients in First Complete Remission65 percentage of patients

Publications by year

1979–2026: 268 publications.

1979
1
1992
3
1993
1
1996
1
1997
4
1998
5
1999
4
2000
5
2001
8
2002
7
2003
7
2004
8
2005
7
2006
12
2007
19
2008
15
2009
15
2010
10
2011
9
2012
17
2013
16
2014
16
2015
11
2016
9
2017
5
2018
2
2019
6
2020
11
2021
7
2022
11
2023
2
2024
5
2025
6
2026
3

Publications by indication

Acquired Immunodeficiency Syndrome (54)

  • The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy.
    J Infect Dis · 2024 · PMID 38349333 · NCT03212989
  • Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.
    AIDS Res Hum Retroviruses · 2019 · PMID 28636433 · NCT02707900
  • Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes.
    PLoS Pathog · 2015 · PMID 25122219 · NCT02707900
  • Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
    PLoS Pathog · 2014 · PMID 24722454 · NCT02707900
  • Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.
    Hum Vaccin Immunother · 2014 · PMID 23370291 · NCT02707900

Infections (41)

  • Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.
    J Infect Dis · 2022 · PMID 34562096 · NCT03803605
  • Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
    Lancet · 2020 · PMID 32085823 · NCT02336074
  • Broadening community engagement in clinical research: Designing and assessing a pilot crowdsourcing project to obtain community feedback on an HIV clinical trial.
    Clin Trials · 2020 · PMID 32009466 · NCT03803605
  • Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.
    PLoS Pathog · 2015 · PMID 23516360 · NCT02336074
  • Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.
    PLoS One · 2015 · PMID 25007091 · NCT02336074

Leukemia, Myeloid, Acute (26)

  • Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203.
    Leukemia · 2024 · PMID 38830960 · NCT01802333
  • A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
    Leukemia · 2024 · PMID 37935977 · NCT01802333
  • Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
    Am J Hematol · 2022 · PMID 35180323 · NCT02412475
  • A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.
    Haematologica · 2019 · PMID 29567781 · NCT01130506
  • A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
    Leukemia · 2017 · PMID 27795561 · NCT00948064

Multiple Myeloma (21)

  • Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.
    Blood · 2025 · PMID 40834881 · NCT01554852
  • Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial.
    Clin Lymphoma Myeloma Leuk · 2022 · PMID 33478922 · NCT01720875
  • Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
    J Clin Oncol · 2022 · PMID 35377708 · NCT01554852
  • Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials.
    Blood Adv · 2022 · PMID 35790108 · NCT01554852
  • VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
    Clin Lymphoma Myeloma Leuk · 2017 · PMID 27025160 · NCT00773838

Lymphoma (15)

  • Interplay between C-type lectin receptors and microRNAs in cellular homeostasis and immune response.
    FEBS J · 2021 · PMID 33085815 · NCT03713320
  • Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.
    Clin Epigenetics · 2020 · PMID 31823832 · NCT01422499
  • Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
    Invest New Drugs · 2016 · PMID 26091915 · NCT01169532
  • A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.
    Leuk Lymphoma · 2016 · PMID 25213183 · NCT00561418
  • Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
    Biol Blood Marrow Transplant · 2016 · PMID 26071868 · NCT01421173

Stomach Neoplasms (12)

  • Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.
    Lancet Oncol · 2008 · PMID 18207460 · NCT01045538
  • The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma.
    Ann Surg Oncol · 2008 · PMID 18470569 · NCT01045538
  • FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
    Oncologist · 2007 · PMID 17962618 · NCT01045538
  • Histone modifications as markers of cancer prognosis: a cellular view.
    Br J Cancer · 2007 · PMID 17592497 · NCT01045538
  • A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
    Ann Oncol · 2005 · PMID 15319239 · NCT01045538

Publications by journal

Trial-results highlights

In a study on Lung Neoplasms (NCT00128102), the median Overall Survival (OS) was 30.7 Weeks for the Vorinostat arm, compared to 27.1 Weeks for the Placebo arm. Regarding adverse events (AEs) in this study, 327 Participants in the Vorinostat arm experienced an AE, while 311 Participants in the Placebo arm experienced an AE. For AEs characterized as Grade 3 or Grade 4, 165 Participants in the Vorinostat arm experienced these, versus 146 Participants in the Placebo arm. The number of Participants who discontinued study treatment due to an AE was 60 in the Vorinostat arm and 49 in the Placebo arm.

For Multiple Myeloma, a study (NCT00773747) reported a median Progression-Free Survival (PFS) of 7.63 Months for the Vorinostat + Bortezomib arm, compared to 6.83 Months for the Placebo + Bortezomib arm. In another study where the indication was not specified (NCT00473889), the median Overall Survival was 11.0 Months for the Vorinostat + Paclitaxel + Carboplatin arm, versus 14.0 Months for the Placebo + Paclitaxel + Carboplatin arm.

A study on Astrocytoma (NCT01236560) assessed event-free survival 1 year after enrollment. The reported probabilities were:

  • Arm I (Vorinostat, Phase II Arm A): 41.3 percent probability
  • Arm II (Temozolomide, Phase II Arm B): 59.3 percent probability
  • Arm III (Bevacizumab, Phase II Arm C): 43.8 percent probability
  • Feasibility (Vorinostat): 33.3 percent probability
The Maximum Tolerated Dose (MTD) of Vorinostat in the Feasibility (Vorinostat) arm of this study was 230 mg/sq m over 10 weeks. All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Vorinostat publications (268)

2026 (3 papers)

  1. Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study.
    Gruber TA, Jeha S, Deyell RJ, et al. · Lancet Haematol · 2026 · Derived
    PubMed: PMID 41692013 · NCT02553460 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  2. HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.
    Filippini DM, Cabarrou B, Dupain C, et al. · ESMO Open · 2026 · Derived
    PubMed: PMID 41468684 · NCT04357873 (PEVOsq) · Squamous Cell Carcinoma of Head and Neck
  3. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.
    Davis KL, Yao CC, Zimmerman JAO, et al. · J Natl Compr Canc Netw · 2026 · Derived
    PubMed: PMID 41671463 · NCT05848687 · Precursor Cell Lymphoblastic Leukemia-Lymphoma

2025 (6 papers)

  1. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.
    Tost J, Ak-Aksoy S, Campa D, et al. · Semin Cancer Biol · 2025 · Derived
    PubMed: PMID 39863139 · NCT02349867 · Pancreatic Neoplasms
  2. A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma.
    Pili R, Quinn DI, Adra N, et al. · Cancer Med · 2025 · Derived
    PubMed: PMID 40145367 · NCT02619253 · Carcinoma, Renal Cell
  3. Health-related quality of life in cutaneous T-cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome.
    Ortiz Romero PL, Kim YH, Molloy K, et al. · J Eur Acad Dermatol Venereol · 2025 · Derived
    PubMed: PMID 39315857 · NCT01728805 · Lymphoma, T-Cell, Cutaneous
  4. Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.
    Cash T, Marachelian A, DuBois SG, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 40549985 · NCT03332667 · Neuroblastoma
  5. Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.
    Borcoman E, Cabarrou B, Francisco M, et al. · Nat Cancer · 2025 · Derived
    PubMed: PMID 40588522 · NCT04357873 (PEVOsq) · Squamous Cell Carcinoma of Head and Neck
  6. Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.
    Beer SA, Cairns DA, Pawlyn C, et al. · Blood · 2025 · Derived
    PubMed: PMID 40834881 · NCT01554852 (Myeloma XI) · Multiple Myeloma

2024 (5 papers)

  1. Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203.
    Zhang MY, Othus M, McMillen K, et al. · Leukemia · 2024 · Derived
    PubMed: PMID 38830960 · NCT01802333 · Leukemia, Myeloid, Acute
  2. Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
    Mei M, Chen L, Godfrey J, et al. · Blood · 2024 · Derived
    PubMed: PMID 37339586 · NCT03150329 · Lymphoma, Large B-Cell, Diffuse
  3. Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Godfrey J, Mei M, Chen L, et al. · Haematologica · 2024 · Derived
    PubMed: PMID 37470137 · NCT03150329 · Lymphoma, Large B-Cell, Diffuse
  4. The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy.
    Gay CL, Hanley PJ, Falcinelli SD, et al. · J Infect Dis · 2024 · Derived
    PubMed: PMID 38349333 · NCT03212989 (XTRA) · Acquired Immunodeficiency Syndrome
  5. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
    Garcia-Manero G, Podoltsev NA, Othus M, et al. · Leukemia · 2024 · Derived
    PubMed: PMID 37935977 · NCT01802333 · Leukemia, Myeloid, Acute

2023 (2 papers)

  1. Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat.
    Pan C, Wu QV, Voutsinas J, et al. · Head Neck · 2023 · Derived
    PubMed: PMID 36412064 · NCT02538510 · Squamous Cell Carcinoma of Head and Neck
  2. Proteostasis Modulation in Germline Missense von Hippel Lindau Disease.
    Chittiboina P, Mandal D, Bugarini A, et al. · Clin Cancer Res · 2023 · Derived
    PubMed: PMID 37018064 · NCT02108002 · Hemangioblastoma

2022 (11 papers)

  1. Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal.
    McMahon JH, Evans VA, Lau JSY, et al. · AIDS · 2022 · Trial result
    PubMed: PMID 34586085 · NCT03198559 · HIV Infections
  2. Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial.
    Brown S, Pawlyn C, Tillotson AL, et al. · Clin Lymphoma Myeloma Leuk · 2022 · Trial result
    PubMed: PMID 33478922 · NCT01720875 (MUKfour) · Multiple Myeloma
  3. Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.
    Scully EP, Aga E, Tsibris A, et al. · Clin Infect Dis · 2022 · Derived
    PubMed: PMID 35176755 · NCT03382834 · HIV Infections
  4. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
    Quinn DI, Tsao-Wei DD, Twardowski P, et al. · Invest New Drugs · 2022 · Derived
    PubMed: PMID 33409898 · NCT00363883
  5. Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
    Pommert L, Schafer ES, Malvar J, et al. · Am J Hematol · 2022 · Derived
    PubMed: PMID 35180323 · NCT02412475 · Leukemia, Myeloid, Acute
  6. Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study.
    Haigentz M, Moore P, Bimali M, et al. · Oncologist · 2022 · Derived
    PubMed: PMID 35429391 · NCT01249443 · Breast Neoplasms
  7. Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.
    Gay CL, James KS, Tuyishime M, et al. · J Infect Dis · 2022 · Derived
    PubMed: PMID 34562096 · NCT03803605 · Infections
  8. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
    de Tute RM, Pawlyn C, Cairns DA, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35377708 · NCT01554852 (Myeloma XI) · Multiple Myeloma
  9. Examiner accuracy in cognitive testing in multisite brain-tumor clinical trials: an analysis from the Alliance for Clinical Trials in Oncology.
    Cerhan JH, Anderson SK, Butts AM, et al. · Neurooncol Pract · 2022 · Derived
    PubMed: PMID 31386061 · NCT00731731 · Glioblastoma
  10. Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC).
    Arora SP, Tenner L, Sarantopoulos J, et al. · Br J Cancer · 2022 · Derived
    PubMed: PMID 35739299 · NCT02316340 · Colorectal Neoplasms
  11. Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials.
    Agbuduwe C, Iqbal G, Cairns D, et al. · Blood Adv · 2022 · Derived
    PubMed: PMID 35790108 · NCT01554852 (Myeloma XI) · Multiple Myeloma

2021 (7 papers)

  1. Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.
    Siddiqi T, Frankel P, Beumer JH, et al. · Leuk Lymphoma · 2021 · Derived
    PubMed: PMID 31617432 · NCT01567709 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  2. Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial).
    Ramos JC, Sparano JA, Chadburn A, et al. · Blood · 2021 · Derived
    PubMed: PMID 32430507 · NCT01193842 · Lymphoma, Large B-Cell, Diffuse
  3. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
    Janku F, Park H, Call SG, et al. · Clin Cancer Res · 2021 · Derived
    PubMed: PMID 33055173 · NCT01087554
  4. Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives.
    Garcia AA, Koperniku A, Ferreira JCB, et al. · Trends Pharmacol Sci · 2021 · Derived
    PubMed: PMID 34389161 · NCT02124083 · Niemann-Pick Disease, Type A
  5. Interplay between C-type lectin receptors and microRNAs in cellular homeostasis and immune response.
    Ganguly K, Kishore U, Madan T, et al. · FEBS J · 2021 · Derived
    PubMed: PMID 33085815 · NCT03713320 (SOLAR) · Lymphoma
  6. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
    DuBois SG, Granger MM, Groshen S, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 34270348 · NCT02035137 (N2011-01) · Neuroblastoma
  7. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
    Burke MJ, Kostadinov R, Sposto R, et al. · Clin Cancer Res · 2021 · Derived
    PubMed: PMID 31969338 · NCT01483690 · Precursor Cell Lymphoblastic Leukemia-Lymphoma

2020 (11 papers)

  1. Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.
    Gordon SW, McGuire WP, Shafer DA, et al. · Am J Clin Oncol · 2020 · Trial result
    PubMed: PMID 31305287 · NCT01075113 · Carcinoma, Hepatocellular
  2. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
    Fidler S, Stöhr W, Pace M, et al. · Lancet · 2020 · Trial result
    PubMed: PMID 32085823 · NCT02336074 (RIVER) · Infections
  3. Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.
    van Tilburg CM, Milde T, Witt R, et al. · Clin Epigenetics · 2020 · Derived
    PubMed: PMID 31823832 · NCT01422499 · Lymphoma
  4. Interventions for mycosis fungoides.
    Valipour A, Jäger M, Wu P, et al. · Cochrane Database Syst Rev · 2020 · Derived
    PubMed: PMID 32632956 · NCT02943642 (Resimmune®) · Lymphoma, T-Cell, Cutaneous
  5. Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
    Terranova-Barberio M, Pawlowska N, Dhawan M, et al. · Nat Commun · 2020 · Derived
    PubMed: PMID 32681091 · NCT02395627 · Breast Neoplasms
  6. Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma.
    Spurgeon SE, Sharma K, Claxton DF, et al. · Br J Haematol · 2020 · Derived
    PubMed: PMID 31177537 · NCT00764517 · Leukemia, Lymphocytic, Chronic, B-Cell
  7. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
    Rodriguez CP, Wu QV, Voutsinas J, et al. · Clin Cancer Res · 2020 · Derived
    PubMed: PMID 31796519 · NCT02538510 · Squamous Cell Carcinoma of Head and Neck
  8. Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study.
    Huijberts S, Wang L, de Oliveira RL, et al. · Future Oncol · 2020 · Derived
    PubMed: PMID 32125175 · NCT02836548 · Melanoma
  9. In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.
    Garrido C, Tolstrup M, Søgaard OS, et al. · AIDS · 2020 · Derived
    PubMed: PMID 30830886 · NCT01319383
  10. Broadening community engagement in clinical research: Designing and assessing a pilot crowdsourcing project to obtain community feedback on an HIV clinical trial.
    Day S, Mathews A, Blumberg M, et al. · Clin Trials · 2020 · Derived
    PubMed: PMID 32009466 · NCT03803605 · Infections
  11. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
    Booth L, Poklepovic A, Dent P, et al. · Biochem Pharmacol · 2020 · Derived
    PubMed: PMID 32504550 · NCT02349867 · Pancreatic Neoplasms

2019 (6 papers)

  1. A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target.
    Ibhazehiebo K, Gavrilovici C, de la Hoz CL, et al. · Brain · 2019 · Trial result
    PubMed: PMID 29373639 · NCT03894826 · Drug Resistant Epilepsy
  2. Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.
    Statler A, Othus M, Erba HP, et al. · Blood · 2019 · Derived
    PubMed: PMID 29618479 · NCT01522976 · Myelodysplastic Syndromes
  3. A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.
    Mims AS, Mishra A, Orwick S, et al. · Haematologica · 2019 · Derived
    PubMed: PMID 29567781 · NCT01130506 · Leukemia, Myeloid, Acute
  4. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
    Kim YH, Bagot M, Pinter-Brown L, et al. · Lancet Oncol · 2019 · Derived
    PubMed: PMID 30100375 · NCT01728805 · Lymphoma, T-Cell, Cutaneous
  5. Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
    Ghiaseddin A, Reardon D, Massey W, et al. · Oncologist · 2019 · Derived
    PubMed: PMID 29133513 · NCT01738646 · Glioblastoma
  6. Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.
    Gay CL, DeBenedette MA, Tcherepanova IY, et al. · AIDS Res Hum Retroviruses · 2019 · Background
    PubMed: PMID 28636433 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome

2018 (2 papers)

  1. No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy.
    Mota TM, Rasmussen TA, Rhodes A, et al. · AIDS · 2018 · Trial result
    PubMed: PMID 28301423 · NCT01365065 · HIV Seropositivity
  2. Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.
    Connolly RM, Fackler MJ, Zhang Z, et al. · Breast Cancer Res Treat · 2018 · Trial result
    PubMed: PMID 28918548 · NCT00616967 · Breast Neoplasms

2017 (5 papers)

  1. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
    Siegel DS, Dimopoulos M, Jagannath S, et al. · Clin Lymphoma Myeloma Leuk · 2017 · Trial result
    PubMed: PMID 27025160 · NCT00773838 · Multiple Myeloma
  2. Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO).
    Schmitt T, Mayer-Steinacker R, Mayer F, et al. · Eur J Cancer · 2017 · Derived
    PubMed: PMID 27367154 · NCT00918489 (SAHA-I) · Neoplasm Metastasis
  3. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
    Montalban-Bravo G, Huang X, Naqvi K, et al. · Leukemia · 2017 · Derived
    PubMed: PMID 27795561 · NCT00948064 · Leukemia, Myeloid, Acute
  4. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.
    Archin NM, Kirchherr JL, Sung JA, et al. · J Clin Invest · 2017 · Derived
    PubMed: PMID 28714868 · NCT01319383
  5. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT.
    Choi SW, Braun T, Henig I, et al. · Blood · 2017 · Background
    PubMed: PMID 28784598 · NCT01790568 · Graft vs Host Disease

2016 (9 papers)

  1. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
    Zibelman M, Wong YN, Devarajan K, et al. · Invest New Drugs · 2016 · Trial result
    PubMed: PMID 26091915 · NCT01169532 · Lymphoma
  2. A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
    Ogawa Y, Ogura M, Tobinai K, et al. · Int J Hematol · 2016 · Trial result
    PubMed: PMID 26619834 · NCT00858234 · Multiple Myeloma
  3. A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.
    Hofmeister CC, Williams N, Geyer S, et al. · Leuk Lymphoma · 2016 · Trial result
    PubMed: PMID 25213183 · NCT00561418 · Lymphoma
  4. Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.
    Frankel AE, Woo JH, Ahn C, et al. · Haematologica · 2016 · Trial result
    PubMed: PMID 25795722 · NCT02943642 (Resimmune®) · Lymphoma, T-Cell, Cutaneous
  5. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    Elliott JH, Wightman F, Solomon A, et al. · PLoS Pathog · 2016 · Trial result
    PubMed: PMID 25393648 · NCT01365065 · HIV Seropositivity
  6. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
    Walker BA, Boyle EM, Wardell CP, et al. · J Clin Oncol · 2016 · Derived
    PubMed: PMID 26282654 · NCT01554852 (Myeloma XI) · Multiple Myeloma
  7. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
    Nieto Y, Valdez BC, Thall PF, et al. · Biol Blood Marrow Transplant · 2016 · Derived
    PubMed: PMID 26071868 · NCT01421173 · Lymphoma
  8. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
    Fu S, Hou MM, Naing A, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 25669829 · NCT01339871
  9. Changes of lung tumour volume on CT - prediction of the reliability of assessments.
    Beaumont H, Souchet S, Labatte JM, et al. · Cancer Imaging · 2016 · Derived
    PubMed: PMID 26521238 · NCT00473889

2015 (11 papers)

  1. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.
    Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. · PLoS Pathog · 2015 · Trial result
    PubMed: PMID 23516360 · NCT02336074 (RIVER) · Infections
  2. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
    Matulonis U, Berlin S, Lee H, et al. · Cancer Chemother Pharmacol · 2015 · Trial result
    PubMed: PMID 26119093 · NCT00910000 · Ovarian Neoplasms
  3. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
    Krug LM, Kindler HL, Calvert H, et al. · Lancet Oncol · 2015 · Trial result
    PubMed: PMID 25800891 · NCT00128102 · Lung Neoplasms
  4. Phase II trial of vorinostat in advanced melanoma.
    Haas NB, Quirt I, Hotte S, et al. · Invest New Drugs · 2015 · Trial result
    PubMed: PMID 24464266 · NCT00121225 · Melanoma
  5. TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.
    Connolly RM, Leal JP, Goetz MP, et al. · J Nucl Med · 2015 · Trial result
    PubMed: PMID 25476537 · NCT00616967 · Breast Neoplasms
  6. Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma.
    Sborov DW, Benson DM, Williams N, et al. · Br J Haematol · 2015 · Derived
    PubMed: PMID 26058589 · NCT00729118 · Multiple Myeloma
  7. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
    Chen R, Frankel P, Popplewell L, et al. · Haematologica · 2015 · Derived
    PubMed: PMID 25596263 · NCT00720876 · Lymphoma
  8. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation.
    Schuetz A, Deleage C, Sereti I, et al. · PLoS Pathog · 2015 · Background
    PubMed: PMID 25503054 · NCT02475915
  9. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes.
    Jones RB, O'Connor R, Mueller S, et al. · PLoS Pathog · 2015 · Background
    PubMed: PMID 25122219 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  10. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.
    Hayton EJ, Rose A, Ibrahimsa U, et al. · PLoS One · 2015 · Background
    PubMed: PMID 25007091 · NCT02336074 (RIVER) · Infections
  11. Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans.
    Choi SW, Gatza E, Hou G, et al. · Blood · 2015 · Background
    PubMed: PMID 25428224 · NCT03167437 · Crohn Disease

2014 (16 papers)

  1. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.
    Siegel DS, Richardson P, Dimopoulos M, et al. · Blood Cancer J · 2014 · Trial result
    PubMed: PMID 24562384 · NCT00642954 · Multiple Myeloma
  2. Use of high-resolution volumetric MR spectroscopic imaging in assessing treatment response of glioblastoma to an HDAC inhibitor.
    Shim H, Wei L, Holder CA, et al. · AJR Am J Roentgenol · 2014 · Trial result
    PubMed: PMID 25055291 · NCT01342757 · Glioblastoma
  3. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
    Reguart N, Rosell R, Cardenal F, et al. · Lung Cancer · 2014 · Trial result
    PubMed: PMID 24636848 · NCT00503971 · Carcinoma, Non-Small-Cell Lung
  4. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    Ogura M, Ando K, Suzuki T, et al. · Br J Haematol · 2014 · Trial result
    PubMed: PMID 24617454 · NCT00875056 · Lymphoma
  5. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
    Kirschbaum M, Gojo I, Goldberg SL, et al. · Br J Haematol · 2014 · Trial result
    PubMed: PMID 25040094 · NCT00479232 · Myelodysplastic Syndromes
  6. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.
    Choi SW, Braun T, Chang L, et al. · Lancet Oncol · 2014 · Trial result
    PubMed: PMID 24295572 · NCT00810602 · Graft vs Host Disease
  7. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.
    Archin NM, Bateson R, Tripathy MK, et al. · J Infect Dis · 2014 · Trial result
    PubMed: PMID 24620025 · NCT01319383
  8. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
    Walter RB, Medeiros BC, Gardner KM, et al. · Haematologica · 2014 · Derived
    PubMed: PMID 24142996 · NCT00895934 · Leukemia, Myeloid, Acute
  9. Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
    Prebet T, Braun T, Beyne-Rauzy O, et al. · Leuk Res · 2014 · Derived
    PubMed: PMID 23953882 · NCT00776503 (GFMVOR2007) · Myelodysplastic Syndromes
  10. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.
    Burke MJ, Lamba JK, Pounds S, et al. · Am J Hematol · 2014 · Derived
    PubMed: PMID 24891274 · NCT00882206 · Lymphoma
  11. Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.
    Bernot KM, Siebenaler RF, Whitman SP, et al. · Leukemia · 2014 · Derived
    PubMed: PMID 23660685 · NCT00357708 · Leukemia, Myeloid, Acute
  12. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
    Wei DG, Chiang V, Fyne E, et al. · PLoS Pathog · 2014 · Background
    PubMed: PMID 24722454 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  13. Niemann-Pick diseases.
    Vanier MT · Handb Clin Neurol · 2014 · Background
    PubMed: PMID 23622394 · NCT02124083 · Niemann-Pick Disease, Type A
  14. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.
    Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, et al. · Hum Vaccin Immunother · 2014 · Background
    PubMed: PMID 23370291 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  15. Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy.
    Cillo AR, Krishnan S, McMahon DK, et al. · PLoS One · 2014 · Background
    PubMed: PMID 24638072 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  16. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
    Bullen CK, Laird GM, Durand CM, et al. · Nat Med · 2014 · Background
    PubMed: PMID 24658076 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome

2013 (16 papers)

  1. Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
    Wada H, Tsuboi R, Kato Y, et al. · J Dermatol · 2013 · Trial result
    PubMed: PMID 22506596 · NCT00771472 · Lymphoma
  2. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.
    Hamlyn E, Ewings FM, Porter K, et al. · PLoS One · 2013 · Trial result
    PubMed: PMID 22952756 · NCT02336074 (RIVER) · Infections
  3. Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.
    Doi T, Hamaguchi T, Shirao K, et al. · Int J Clin Oncol · 2013 · Trial result
    PubMed: PMID 22234637 · NCT00373490 · Neoplasms
  4. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
    Dimopoulos M, Siegel DS, Lonial S, et al. · Lancet Oncol · 2013 · Trial result
    PubMed: PMID 24055414 · NCT00773747 · Multiple Myeloma
  5. Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia.
    Witt O, Milde T, Deubzer HE, et al. · Klin Padiatr · 2013 · Derived
    PubMed: PMID 22915450 · NCT01422499 · Lymphoma
  6. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.
    Weber DM, Graef T, Hussein M, et al. · Clin Lymphoma Myeloma Leuk · 2013 · Derived
    PubMed: PMID 23040438 · NCT00111813 · Multiple Myeloma
  7. Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?
    Raetz EA, Bhatla T · Hematology Am Soc Hematol Educ Program · 2013 · Derived
    PubMed: PMID 23233571 · NCT01483690 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  8. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
    Hummel TR, Wagner L, Ahern C, et al. · Pediatr Blood Cancer · 2013 · Derived
    PubMed: PMID 23554030 · NCT01076530 · Astrocytoma
  9. Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma.
    Amengual JE, Clark-Garvey S, Kalac M, et al. · Blood · 2013 · Derived
    PubMed: PMID 23913470 · NCT00691210 (SAHA) · Lymphoma, Non-Hodgkin
  10. Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?
    Vanham G, Van Gulck E · Retrovirology · 2013 · Background
    PubMed: PMID 22958464 · NCT02336074 (RIVER) · Infections
  11. Short-course antiretroviral therapy in primary HIV infection.
    SPARTAC Trial Investigators, Fidler S, Porter K, et al. · N Engl J Med · 2013 · Background
    PubMed: PMID 23323897 · NCT02336074 (RIVER) · Infections
  12. A cure for HIV: where we've been, and where we're headed.
    Lewin SR · Lancet · 2013 · Background
    PubMed: PMID 23769215 · NCT02475915
  13. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.
    Katlama C, Deeks SG, Autran B, et al. · Lancet · 2013 · Background
    PubMed: PMID 23541541 · NCT02475915
  14. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C, Girault I, Rouzioux C, et al. · Antivir Ther · 2013 · Background
    PubMed: PMID 22865544 · NCT02336074 (RIVER) · Infections
  15. A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.
    Budde LE, Zhang MM, Shustov AR, et al. · Br J Haematol · 2013 · Background
    PubMed: PMID 23356514 · NCT00601718 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  16. Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells.
    Beliakova-Bethell N, Zhang JX, Singhania A, et al. · AIDS · 2013 · Background
    PubMed: PMID 23221426 · NCT02475915

2012 (17 papers)

  1. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo.
    Ramaswamy B, Fiskus W, Cohen B, et al. · Breast Cancer Res Treat · 2012 · Trial result
    PubMed: PMID 22200869 · NCT00368875 · Breast Neoplasms
  2. Redefining the viral reservoirs that prevent HIV-1 eradication.
    Eisele E, Siliciano RF · Immunity · 2012 · Trial result
    PubMed: PMID 22999944 · NCT02336074 (RIVER) · Infections
  3. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.
    Dummer R, Beyer M, Hymes K, et al. · Leuk Lymphoma · 2012 · Trial result
    PubMed: PMID 22239668 · NCT00127101 · Lymphoma
  4. HIV: Shock and kill.
    Deeks SG · Nature · 2012 · Trial result
    PubMed: PMID 22836995 · NCT02336074 (RIVER) · Infections
  5. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure.
    Chun TW, Fauci AS · AIDS · 2012 · Trial result
    PubMed: PMID 22472858 · NCT02336074 (RIVER) · Infections
  6. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Archin NM, Liberty AL, Kashuba AD, et al. · Nature · 2012 · Trial result
    PubMed: PMID 22837004 · NCT01319383
  7. Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.
    Walter RB, Medeiros BC, Powell BL, et al. · Haematologica · 2012 · Derived
    PubMed: PMID 22133771 · NCT00673153 · Leukemia, Myeloid, Acute
  8. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
    Sheehy SH, Duncan CJ, Elias SC, et al. · Mol Ther · 2012 · Background
    PubMed: PMID 21862998 · NCT02336074 (RIVER) · Infections
  9. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.
    Shan L, Deng K, Shroff NS, et al. · Immunity · 2012 · Background
    PubMed: PMID 22406268 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  10. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.
    Paton NI, Goodall RL, Dunn DT, et al. · JAMA · 2012 · Background
    PubMed: PMID 22820788 · NCT02475915
  11. Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir.
    Koelsch KK, Boesecke C, McBride K, et al. · AIDS · 2012 · Background
    PubMed: PMID 21860347 · NCT02336074 (RIVER) · Infections
  12. Towards an HIV cure: a global scientific strategy.
    International AIDS Society Scientific Working Group on HIV Cure, Deeks SG, Autran B, et al. · Nat Rev Immunol · 2012 · Background
    PubMed: PMID 22814509 · NCT02336074 (RIVER) · Infections
  13. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection.
    Evering TH, Mehandru S, Racz P, et al. · PLoS Pathog · 2012 · Background
    PubMed: PMID 22319447 · NCT02336074 (RIVER) · Infections
  14. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.
    Colloca S, Barnes E, Folgori A, et al. · Sci Transl Med · 2012 · Background
    PubMed: PMID 22218691 · NCT02336074 (RIVER) · Infections
  15. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.
    Barnes E, Folgori A, Capone S, et al. · Sci Transl Med · 2012 · Background
    PubMed: PMID 22218690 · NCT02336074 (RIVER) · Infections
  16. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection.
    Archin NM, Vaidya NK, Kuruc JD, et al. · Proc Natl Acad Sci U S A · 2012 · Background
    PubMed: PMID 22645358 · NCT02336074 (RIVER) · Infections
  17. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection.
    Ananworanich J, Schuetz A, Vandergeeten C, et al. · PLoS One · 2012 · Background
    PubMed: PMID 22479485 · NCT02475915

2011 (9 papers)

  1. A phase 2 study of vorinostat in acute myeloid leukemia.
    Schaefer EW, Loaiza-Bonilla A, Juckett M, et al. · Haematologica · 2011 · Derived
    PubMed: PMID 19794082 · NCT00305773 · Leukemia, Myeloid, Acute
  2. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    Kirschbaum M, Frankel P, Popplewell L, et al. · J Clin Oncol · 2011 · Derived
    PubMed: PMID 21300924 · NCT00253630 · Lymphoma, Follicular
  3. Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy.
    Bratland A, Dueland S, Hollywood D, et al. · Radiat Oncol · 2011 · Derived
    PubMed: PMID 21473790 · NCT00455351 (PRAVO) · Pelvic Neoplasms
  4. Viral vectors as vaccine platforms: deployment in sight.
    Rollier CS, Reyes-Sandoval A, Cottingham MG, et al. · Curr Opin Immunol · 2011 · Background
    PubMed: PMID 21514130 · NCT02336074 (RIVER) · Infections
  5. Introduction: challenges to finding a cure for HIV infection.
    Richman DD · Curr Opin HIV AIDS · 2011 · Background
    PubMed: PMID 21242886 · NCT02336074 (RIVER) · Infections
  6. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders.
    Piconi S, Parisotto S, Rizzardini G, et al. · Blood · 2011 · Background
    PubMed: PMID 21576701 · NCT02475915
  7. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
    Gandhi RT, Zheng L, Bosch RJ, et al. · PLoS Med · 2011 · Background
    PubMed: PMID 20711481 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  8. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer.
    Dinarello CA, Fossati G, Mascagni P, et al. · Mol Med · 2011 · Background
    PubMed: PMID 21556484 · NCT03167437 · Crohn Disease
  9. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.
    de Lima M, Giralt S, Thall PF, et al. · Cancer · 2011 · Background
    PubMed: PMID 20672358 · NCT01617226 (RAvVA) · Leukemia, Myeloid, Acute

2010 (10 papers)

  1. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
    Ree AH, Dueland S, Folkvord S, et al. · Lancet Oncol · 2010 · Trial result
    PubMed: PMID 20378407 · NCT00455351 (PRAVO) · Pelvic Neoplasms
  2. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer.
    Munster PN, Rubin EH, Van Belle S, et al. · Clin Cancer Res · 2010 · Trial result
    PubMed: PMID 19887475 · NCT00632931
  3. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
    Duvic M, Olsen EA, Breneman D, et al. · Clin Lymphoma Myeloma · 2010 · Trial result
    PubMed: PMID 19951879 · NCT00907738
  4. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors.
    Archin NM, Keedy KS, Espeseth A, et al. · AIDS · 2010 · Trial result
    PubMed: PMID 19590405 · NCT02336074 (RIVER) · Infections
  5. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.
    Watanabe T, Kato H, Kobayashi Y, et al. · Cancer Sci · 2010 · Derived
    PubMed: PMID 19817748 · NCT00127140 · Lymphoma
  6. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
    Zelenetz AD, Abramson JS, Advani RH, et al. · J Natl Compr Canc Netw · 2010 · Background
    PubMed: PMID 20202462 · NCT01187446 · Lymphoma, T-Cell, Cutaneous
  7. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.
    Routy JP, Boulassel MR, Yassine-Diab B, et al. · Clin Immunol · 2010 · Background
    PubMed: PMID 19889582 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  8. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
    Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20026804 · NCT01617226 (RAvVA) · Leukemia, Myeloid, Acute
  9. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
    Döhner H, Estey EH, Amadori S, et al. · Blood · 2010 · Background
    PubMed: PMID 19880497 · NCT01617226 (RAvVA) · Leukemia, Myeloid, Acute
  10. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    Archin NM, Cheema M, Parker D, et al. · PLoS One · 2010 · Background
    PubMed: PMID 20186346 · NCT02336074 (RIVER) · Infections

2009 (15 papers)

  1. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.
    Hütter G, Nowak D, Mossner M, et al. · N Engl J Med · 2009 · Trial result
    PubMed: PMID 19213682 · NCT02336074 (RIVER) · Infections
  2. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs.
    Coiras M, López-Huertas MR, Pérez-Olmeda M, et al. · Nat Rev Microbiol · 2009 · Trial result
    PubMed: PMID 19834480 · NCT02336074 (RIVER) · Infections
  3. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
    Woyach JA, Kloos RT, Ringel MD, et al. · J Clin Endocrinol Metab · 2009 · Derived
    PubMed: PMID 18854394 · NCT00134043 · Adenocarcinoma, Follicular
  4. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
    Vardiman JW, Thiele J, Arber DA, et al. · Blood · 2009 · Background
    PubMed: PMID 19357394 · NCT01617226 (RAvVA) · Leukemia, Myeloid, Acute
  5. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
    Vansteenkiste J, Van Cutsem E, Dumez H, et al. · Invest New Drugs · 2009 · Background
    PubMed: PMID 18425418 · NCT00126451 · Breast Neoplasms
  6. The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90.
    Tcherepanova I, Starr A, Lackford B, et al. · PLoS One · 2009 · Background
    PubMed: PMID 19516896 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  7. Clinical studies of histone deacetylase inhibitors.
    Prince HM, Bishton MJ, Harrison SJ, et al. · Clin Cancer Res · 2009 · Background
    PubMed: PMID 19509172 · NCT02475915
  8. Elevated FOSB-expression; a potential marker of valproate sensitivity in AML.
    Khanim FL, Bradbury CA, Arrazi J, et al. · Br J Haematol · 2009 · Background
    PubMed: PMID 19036090 · NCT01617226 (RAvVA) · Leukemia, Myeloid, Acute
  9. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.
    Jabbour E, Giralt S, Kantarjian H, et al. · Cancer · 2009 · Background
    PubMed: PMID 19235255 · NCT01617226 (RAvVA) · Leukemia, Myeloid, Acute
  10. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.
    Fujiwara Y, Yamamoto N, Yamada Y, et al. · Cancer Sci · 2009 · Background
    PubMed: PMID 19575752 · NCT00127127 · Neoplasms
  11. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
    Contreras X, Schweneker M, Chen CS, et al. · J Biol Chem · 2009 · Background
    PubMed: PMID 19136668 · NCT02336074 (RIVER) · Infections
  12. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.
    Chomont N, El-Far M, Ancuta P, et al. · Nat Med · 2009 · Background
    PubMed: PMID 19543283 · NCT02475915
  13. Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response.
    Calderhead DM, DeBenedette MA, Ketteringham H, et al. · J Immunother · 2009 · Background
    PubMed: PMID 18779746 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  14. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.
    Archin NM, Espeseth A, Parker D, et al. · AIDS Res Hum Retroviruses · 2009 · Background
    PubMed: PMID 19239360 · NCT02336074 (RIVER) · Infections
  15. Maraviroc: pharmacokinetics and drug interactions.
    Abel S, Back DJ, Vourvahis M, et al. · Antivir Ther · 2009 · Background
    PubMed: PMID 19704163 · NCT02475915

2008 (15 papers)

  1. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.
    Richardson P, Mitsiades C, Colson K, et al. · Leuk Lymphoma · 2008 · Trial result
    PubMed: PMID 18297527 · NCT00109109 · Multiple Myeloma
  2. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.
    Weichert W, Röske A, Gekeler V, et al. · Lancet Oncol · 2008 · Background
    PubMed: PMID 18207460 · NCT01045538 · Stomach Neoplasms
  3. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency.
    Tyagi M, Karn J · EMBO J · 2008 · Background
    PubMed: PMID 18007589 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  4. Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection.
    Tcherepanova I, Harris J, Starr A, et al. · PLoS One · 2008 · Background
    PubMed: PMID 18231576 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  5. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier.
    Tatsis N, Blejer A, Lasaro MO, et al. · Mol Ther · 2008 · Background
    PubMed: PMID 17228314 · NCT02336074 (RIVER) · Infections
  6. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir.
    Sagot-Lerolle N, Lamine A, Chaix ML, et al. · AIDS · 2008 · Background
    PubMed: PMID 18525257 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  7. The potential of histone deacetylase inhibitors for the treatment of multiple myeloma.
    Prince HM, Bishton M, Harrison S, et al. · Leuk Lymphoma · 2008 · Background
    PubMed: PMID 18297514 · NCT01297764 (QUAD) · Multiple Myeloma
  8. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma.
    Park YS, Jin MY, Kim YJ, et al. · Ann Surg Oncol · 2008 · Background
    PubMed: PMID 18470569 · NCT01045538 · Stomach Neoplasms
  9. Design and pre-clinical evaluation of a universal HIV-1 vaccine.
    Létourneau S, Im EJ, Mashishi T, et al. · PLoS One · 2008 · Background
    PubMed: PMID 17912361 · NCT02336074 (RIVER) · Infections
  10. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter.
    Jiang G, Espeseth A, Hazuda DJ, et al. · J Virol · 2008 · Background
    PubMed: PMID 17670825 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  11. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
    Garcia-Manero G, Yang H, Bueso-Ramos C, et al. · Blood · 2008 · Background
    PubMed: PMID 17962510 · NCT01617226 (RAvVA) · Leukemia, Myeloid, Acute
  12. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
    Fantin VR, Loboda A, Paweletz CP, et al. · Cancer Res · 2008 · Background
    PubMed: PMID 18483262 · NCT00091559 · Lymphoma, T-Cell, Cutaneous
  13. Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent.
    DeBenedette MA, Calderhead DM, Ketteringham H, et al. · J Immunol · 2008 · Background
    PubMed: PMID 18832685 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  14. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
    Crump M, Coiffier B, Jacobsen ED, et al. · Ann Oncol · 2008 · Background
    PubMed: PMID 18296419 · NCT00097929 · Lymphoma, Large B-Cell, Diffuse
  15. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    Archin NM, Eron JJ, Palmer S, et al. · AIDS · 2008 · Background
    PubMed: PMID 18525258 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome

2007 (19 papers)

  1. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer.
    Rubin EH, Agrawal NG, Friedman EJ, et al. · Clin Cancer Res · 2007 · Trial result
    PubMed: PMID 17145826 · NCT00750178 · Neoplasms
  2. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
    Weber DM, Chen C, Niesvizky R, et al. · N Engl J Med · 2007 · Background
    PubMed: PMID 18032763 · NCT01297764 (QUAD) · Multiple Myeloma
  3. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
    ten Cate B, Samplonius DF, Bijma T, et al. · Leukemia · 2007 · Background
    PubMed: PMID 17122863 · NCT01039363 · Leukemia, Myeloid, Acute
  4. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
    Soriano AO, Yang H, Faderl S, et al. · Blood · 2007 · Background
    PubMed: PMID 17596541 · NCT01617226 (RAvVA) · Leukemia, Myeloid, Acute
  5. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
    Siliciano JD, Lai J, Callender M, et al. · J Infect Dis · 2007 · Background
    PubMed: PMID 17299713 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  6. The adult form of Niemann-Pick disease type C.
    Sévin M, Lesca G, Baumann N, et al. · Brain · 2007 · Background
    PubMed: PMID 17003072 · NCT02124083 · Niemann-Pick Disease, Type A
  7. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
    Olsen EA, Kim YH, Kuzel TM, et al. · J Clin Oncol · 2007 · Background
    PubMed: PMID 17577020 · NCT00091559 · Lymphoma, T-Cell, Cutaneous
  8. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).
    Olsen E, Vonderheid E, Pimpinelli N, et al. · Blood · 2007 · Background
    PubMed: PMID 17540844 · NCT01187446 · Lymphoma, T-Cell, Cutaneous
  9. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing.
    Marban C, Suzanne S, Dequiedt F, et al. · EMBO J · 2007 · Background
    PubMed: PMID 17245431 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  10. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
    Mann BS, Johnson JR, Cohen MH, et al. · Oncologist · 2007 · Background
    PubMed: PMID 17962618 · NCT01045538 · Stomach Neoplasms
  11. Histone modifications as markers of cancer prognosis: a cellular view.
    Kurdistani SK · Br J Cancer · 2007 · Background
    PubMed: PMID 17592497 · NCT01045538 · Stomach Neoplasms
  12. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
    Kuhn DJ, Chen Q, Voorhees PM, et al. · Blood · 2007 · Background
    PubMed: PMID 17591945 · NCT01297764 (QUAD) · Multiple Myeloma
  13. Acute HIV infection: the impact of anti-retroviral treatment on cellular immune responses.
    Hicks CB, Gay C, Ferrari G, et al. · Clin Exp Immunol · 2007 · Background
    PubMed: PMID 17590167 · NCT02336074 (RIVER) · Infections
  14. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older.
    Eom KS, Kim HJ, Min WS, et al. · Eur J Haematol · 2007 · Background
    PubMed: PMID 17916082 · NCT01039363 · Leukemia, Myeloid, Acute
  15. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.
    Emanuele S, Lauricella M, Carlisi D, et al. · Apoptosis · 2007 · Background
    PubMed: PMID 17351739 · NCT01132911 · Lymphoma
  16. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency.
    du Chéné I, Basyuk E, Lin YL, et al. · EMBO J · 2007 · Background
    PubMed: PMID 17245432 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  17. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M, Spencer A, Attal M, et al. · N Engl J Med · 2007 · Background
    PubMed: PMID 18032762 · NCT01297764 (QUAD) · Multiple Myeloma
  18. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
    Demo SD, Kirk CJ, Aujay MA, et al. · Cancer Res · 2007 · Background
    PubMed: PMID 17616698 · NCT01297764 (QUAD) · Multiple Myeloma
  19. Intermittent therapy for the treatment of chronic HIV infection.
    Ananworanich J, Hirschel B · AIDS · 2007 · Background
    PubMed: PMID 17197802 · NCT02475915

2006 (12 papers)

  1. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation.
    Williams SA, Chen LF, Kwon H, et al. · EMBO J · 2006 · Background
    PubMed: PMID 16319923 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  2. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins.
    Van Gulck ER, Ponsaerts P, Heyndrickx L, et al. · Blood · 2006 · Background
    PubMed: PMID 16263796 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  3. Treatment of acute myelogenous leukemia with outpatient azacitidine.
    Sudan N, Rossetti JM, Shadduck RK, et al. · Cancer · 2006 · Background
    PubMed: PMID 16967444 · NCT01617226 (RAvVA) · Leukemia, Myeloid, Acute
  4. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.
    Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, et al. · Blood · 2006 · Background
    PubMed: PMID 16675713 · NCT01039363 · Leukemia, Myeloid, Acute
  5. The immunoregulatory effects of HIV-1 Nef on dendritic cells and the pathogenesis of AIDS.
    Quaranta MG, Mattioli B, Giordani L, et al. · FASEB J · 2006 · Background
    PubMed: PMID 17077296 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  6. Cushing's syndrome.
    Newell-Price J, Bertagna X, Grossman AB, et al. · Lancet · 2006 · Background
    PubMed: PMID 16698415 · NCT04339751 · Pituitary ACTH Hypersecretion
  7. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
    Lonial S, Waller EK, Richardson PG, et al. · Blood · 2006 · Background
    PubMed: PMID 16099887 · NCT01297764 (QUAD) · Multiple Myeloma
  8. Transcriptional repression of human immunodeficiency virus type 1 by AP-4.
    Imai K, Okamoto T · J Biol Chem · 2006 · Background
    PubMed: PMID 16540471 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  9. International uniform response criteria for multiple myeloma.
    Durie BG, Harousseau JL, Miguel JS, et al. · Leukemia · 2006 · Background
    PubMed: PMID 16855634 · NCT01297764 (QUAD) · Multiple Myeloma
  10. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.
    Dorrell L, Yang H, Ondondo B, et al. · J Virol · 2006 · Background
    PubMed: PMID 16641264 · NCT02336074 (RIVER) · Infections
  11. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). 1932.
    Cushing H · Obes Res · 2006 · Background
    PubMed: PMID 16353601 · NCT04339751 · Pituitary ACTH Hypersecretion
  12. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE, Peart MJ, Johnstone RW, et al. · Nat Rev Drug Discov · 2006 · Background
    PubMed: PMID 16955068 · NCT02336074 (RIVER) · Infections

2005 (7 papers)

  1. Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape.
    Majumder B, Janket ML, Schafer EA, et al. · J Virol · 2005 · Background
    PubMed: PMID 15956545 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  2. Histone-deacetylase inhibitors for the treatment of cancer.
    Lindemann RK, Gabrielli B, Johnstone RW, et al. · Cell Cycle · 2005 · Background
    PubMed: PMID 15153801 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  3. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.
    Lehrman G, Hogue IB, Palmer S, et al. · Lancet · 2005 · Background
    PubMed: PMID 16099290 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  4. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.
    Kinloch-de Loes S, Hoen B, Smith DE, et al. · J Infect Dis · 2005 · Background
    PubMed: PMID 16028129 · NCT02336074 (RIVER) · Infections
  5. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
    Kelly WK, O'Connor OA, Krug LM, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15897550 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  6. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
    Hong YS, Song SY, Lee SI, et al. · Ann Oncol · 2005 · Background
    PubMed: PMID 15319239 · NCT01045538 · Stomach Neoplasms
  7. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
    Bali P, Pranpat M, Bradner J, et al. · J Biol Chem · 2005 · Background
    PubMed: PMID 15937340 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome

2004 (8 papers)

  1. Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors.
    Ylisastigui L, Coull JJ, Rucker VC, et al. · J Infect Dis · 2004 · Background
    PubMed: PMID 15378435 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  2. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression.
    Ylisastigui L, Archin NM, Lehrman G, et al. · AIDS · 2004 · Background
    PubMed: PMID 15166525 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  3. HDAC inhibitors for the treatment of cancer.
    Secrist JP, Zhou X, Richon VM, et al. · Curr Opin Investig Drugs · 2004 · Background
    PubMed: PMID 14763127 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  4. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S, et al. · Clin Cancer Res · 2004 · Background
    PubMed: PMID 15173093 · NCT01132911 · Lymphoma
  5. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.
    Mitsiades CS, Mitsiades NS, McMullan CJ, et al. · Proc Natl Acad Sci U S A · 2004 · Background
    PubMed: PMID 14695887 · NCT01132911 · Lymphoma
  6. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector.
    Kostense S, Koudstaal W, Sprangers M, et al. · AIDS · 2004 · Background
    PubMed: PMID 15166541 · NCT02336074 (RIVER) · Infections
  7. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
    Cheson BD, Bennett JM, Kopecky KJ, et al. · J Clin Oncol · 2004 · Background
    PubMed: PMID 14673054 · NCT01617226 (RAvVA) · Leukemia, Myeloid, Acute
  8. Diagnosis and complications of Cushing's syndrome: a consensus statement.
    Arnaldi G, Angeli A, Atkinson AB, et al. · J Clin Endocrinol Metab · 2004 · Background
    PubMed: PMID 14671138 · NCT04339751 · Pituitary ACTH Hypersecretion

2003 (7 papers)

  1. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints.
    Warrener R, Beamish H, Burgess A, et al. · FASEB J · 2003 · Background
    PubMed: PMID 12824307 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  2. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.
    Siliciano JD, Kajdas J, Finzi D, et al. · Nat Med · 2003 · Background
    PubMed: PMID 12754504 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  3. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
    Nimmanapalli R, Fuino L, Stobaugh C, et al. · Blood · 2003 · Background
    PubMed: PMID 12446442 · NCT01039363 · Leukemia, Myeloid, Acute
  4. Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
    Mitsiades N, Mitsiades CS, Richardson PG, et al. · Blood · 2003 · Background
    PubMed: PMID 12531799 · NCT01297764 (QUAD) · Multiple Myeloma
  5. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
    Koizumi W, Saigenji K, Ujiie S, et al. · Oncology · 2003 · Background
    PubMed: PMID 12697963 · NCT01045538 · Stomach Neoplasms
  6. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
    Kim TW, Kang YK, Ahn JH, et al. · Ann Oncol · 2003 · Background
    PubMed: PMID 12453857 · NCT01045538 · Stomach Neoplasms
  7. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines.
    Glaser KB, Staver MJ, Waring JF, et al. · Mol Cancer Ther · 2003 · Background
    PubMed: PMID 12589032 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome

2002 (7 papers)

  1. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.
    Novitsky V, Cao H, Rybak N, et al. · J Virol · 2002 · Background
    PubMed: PMID 12239290 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  2. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
    Munster PN, Troso-Sandoval T, Rosen N, et al. · Cancer Res · 2002 · Background
    PubMed: PMID 11731433 · NCT00416130 · Breast Neoplasms
  3. Histone deacetylases and cancer: causes and therapies.
    Marks P, Rifkind RA, Richon VM, et al. · Nat Rev Cancer · 2002 · Background
    PubMed: PMID 11902574 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  4. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
    Johnstone RW · Nat Rev Drug Discov · 2002 · Background
    PubMed: PMID 12120280 · NCT01039363 · Leukemia, Myeloid, Acute
  5. Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat.
    He G, Margolis DM · Mol Cell Biol · 2002 · Background
    PubMed: PMID 11940654 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  6. Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides.
    Coull JJ, He G, Melander C, et al. · J Virol · 2002 · Background
    PubMed: PMID 12414976 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  7. Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection.
    Addo MM, Yu XG, Rosenberg ES, et al. · DNA Cell Biol · 2002 · Background
    PubMed: PMID 12396610 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome

2001 (8 papers)

  1. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.
    Ruefli AA, Ausserlechner MJ, Bernhard D, et al. · Proc Natl Acad Sci U S A · 2001 · Background
    PubMed: PMID 11535817 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  2. Niemann-Pick type C: a disorder of cellular cholesterol trafficking.
    Ory DS · Biochim Biophys Acta · 2001 · Background
    PubMed: PMID 11111100 · NCT02124083 · Niemann-Pick Disease, Type A
  3. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy.
    Ngo-Giang-Huong N, Deveau C, Da Silva I, et al. · AIDS · 2001 · Background
    PubMed: PMID 11371680 · NCT02336074 (RIVER) · Infections
  4. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
    Huang L, Pardee AB · Mol Med · 2001 · Background
    PubMed: PMID 11126200 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  5. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
    He LZ, Tolentino T, Grayson P, et al. · J Clin Invest · 2001 · Background
    PubMed: PMID 11696577 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  6. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF, Beitz J, Chen G, et al. · Clin Cancer Res · 2001 · Background
    PubMed: PMID 11410481 · NCT01039363 · Leukemia, Myeloid, Acute
  7. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination.
    Barouch DH, Santra S, Kuroda MJ, et al. · J Virol · 2001 · Background
    PubMed: PMID 11333896 · NCT02336074 (RIVER) · Infections
  8. Vpr is preferentially targeted by CTL during HIV-1 infection.
    Altfeld M, Addo MM, Eldridge RL, et al. · J Immunol · 2001 · Background
    PubMed: PMID 11509618 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome

2000 (5 papers)

  1. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.
    Wijermans P, Lübbert M, Verhoef G, et al. · J Clin Oncol · 2000 · Background
    PubMed: PMID 10694544 · NCT01617226 (RAvVA) · Leukemia, Myeloid, Acute
  2. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53.
    Vrana JA, Decker RH, Johnson CR, et al. · Oncogene · 2000 · Background
    PubMed: PMID 10597302 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  3. Von Hippel-Lindau syndrome. A pleomorphic condition.
    Friedrich CA · Cancer · 2000 · Background
    PubMed: PMID 10630173 · NCT02108002 · Hemangioblastoma
  4. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.
    Coull JJ, Romerio F, Sun JM, et al. · J Virol · 2000 · Background
    PubMed: PMID 10888618 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  5. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM, Agus DB, Scher HI, et al. · Cancer Res · 2000 · Background
    PubMed: PMID 11016644 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome

1999 (4 papers)

  1. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.
    Schmitz JE, Kuroda MJ, Santra S, et al. · Science · 1999 · Background
    PubMed: PMID 9933172 · NCT02336074 (RIVER) · Infections
  2. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.
    Hanke T, Samuel RV, Blanchard TJ, et al. · J Virol · 1999 · Background
    PubMed: PMID 10438842 · NCT02336074 (RIVER) · Infections
  3. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.
    Finzi D, Blankson J, Siliciano JD, et al. · Nat Med · 1999 · Background
    PubMed: PMID 10229227 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  4. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors.
    Cassidy J, Dirix L, Bissett D, et al. · Clin Cancer Res · 1999 · Background
    PubMed: PMID 9829739 · NCT01045538 · Stomach Neoplasms

1998 (5 papers)

  1. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.
    Richon VM, Emiliani S, Verdin E, et al. · Proc Natl Acad Sci U S A · 1998 · Background
    PubMed: PMID 9501205 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  2. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells.
    Drexler I, Heller K, Wahren B, et al. · J Gen Virol · 1998 · Background
    PubMed: PMID 9472619 · NCT02336074 (RIVER) · Infections
  3. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.
    Chun TW, Stuyver L, Mizell SB, et al. · Proc Natl Acad Sci U S A · 1998 · Background
    PubMed: PMID 9371822 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  4. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
    Budman DR, Meropol NJ, Reigner B, et al. · J Clin Oncol · 1998 · Background
    PubMed: PMID 9586893 · NCT01045538 · Stomach Neoplasms
  5. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.
    Bladé J, Samson D, Reece D, et al. · Br J Haematol · 1998 · Background
    PubMed: PMID 9753033 · NCT01297764 (QUAD) · Multiple Myeloma

1997 (4 papers)

  1. Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF.
    Romerio F, Gabriel MN, Margolis DM, et al. · J Virol · 1997 · Background
    PubMed: PMID 9371597 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  2. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Glimelius B, Ekström K, Hoffman K, et al. · Ann Oncol · 1997 · Background
    PubMed: PMID 9093725 · NCT01045538 · Stomach Neoplasms
  3. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
    Finzi D, Hermankova M, Pierson T, et al. · Science · 1997 · Background
    PubMed: PMID 9360927 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome
  4. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
    Chun TW, Carruth L, Finzi D, et al. · Nature · 1997 · Background
    PubMed: PMID 9144289 · NCT02707900 (VORVAX) · Acquired Immunodeficiency Syndrome

1996 (1 paper)

  1. A rational approach to radiological screening in von Hippel-Lindau disease.
    Harries RW · J Med Screen · 1996 · Background
    PubMed: PMID 8790493 · NCT02108002 · Hemangioblastoma

1993 (1 paper)

  1. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Kim NK, Park YS, Heo DS, et al. · Cancer · 1993 · Background
    PubMed: PMID 8508349 · NCT01045538 · Stomach Neoplasms

1992 (3 papers)

  1. Nonreplicating vaccinia vector efficiently expresses recombinant genes.
    Sutter G, Moss B · Proc Natl Acad Sci U S A · 1992 · Background
    PubMed: PMID 1438287 · NCT02336074 (RIVER) · Infections
  2. Three cases of 16q duplication.
    Maher ER, Willatt L, Cuthbert G, et al. · J Med Genet · 1992 · Background
    PubMed: PMID 1820771 · NCT02108002 · Hemangioblastoma
  3. 5-Fluorouracil by protracted venous infusion: a review of recent clinical studies.
    Hansen RM · Cancer Invest · 1992 · Background
    PubMed: PMID 1747791 · NCT01045538 · Stomach Neoplasms

1979 (1 paper)

  1. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)].
    Mayr A, Stickl H, Müller HK, et al. · Zentralbl Bakteriol B · 1979 · Background
    PubMed: PMID 219640 · NCT02336074 (RIVER) · Infections

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).